Skip to main content
SpringerLink
Log in

A Practical Approach to Patients with Refractory Helicobacter pylori Infection, or Who Are Re-Infected After Standard Therapy

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The vast majority of recurrences of Helicobacter pylori infection after apparent eradication are observed during the first year. Almost all of these early recurrences are due to recrudescence rather than reinfection by a new strain. After the first year, the recurrence rates approximate to the rate of natural acquisition of H. pylori infection. By contrast, in developing countries, higher rates of recurrence suggest a major role of real reinfection.

Important predictive factors of H. pylori treatment success are compliance and bacterial susceptibility to antibiotics. The new 1-week triple therapies, based on a proton pump inhibitor (PPI) and 2 antibiotics, lead to treatment discontinuation but rarely. If containing a nitroimidazole, their efficacy is reduced to 60 to 80% by pretreatment in vitro resistance. The prevalence of nitroimidazole resistance varies dependent on the geographical area, with rates over 50% in tropical regions. Resistance against macrolides hinders treatment success in 50 to 80% of patients. In the US, south-western Europe and Japan the prevalence of macrolide resistance amounts to about 10%, in other countries about 3%.

After failed treatment, acquired resistance is frequent. Testing for resistance is recommended to facilitate the decision for an alternative triple therapy or for quadruple therapy comprising bismuth, metronidazole, tetracycline and a PPI. It seems reasonable to increase the dose of PPI in a retreatment regimen containing amoxicillin. Post-treatment double resistance against nitroimidazoles and macrolides reduces the success of most of the currently evaluated retreatment regimens. To overcome double resistance, high dose PPI plus amoxicillin is one approach, beside other experimental multidrug treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Malfertheiner P, Megraud F, O’Morain C, et al. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9(1): 1–2

    CAS  Google Scholar 

  2. Yamada TD, Ahnen D, Alpers DH. NIH. Consensus conference: Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272(l): 65–9

    Article  Google Scholar 

  3. Murray DM, DuPont HL, Cooperstock M, et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl. 1: S268–73

    Article  PubMed  Google Scholar 

  4. McColl EEL, el-Nujumi A, Murray IS, et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998; 42: 618–22

    Article  PubMed  CAS  Google Scholar 

  5. Phull PS, Ryder SD, Halliday D, et al. The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease: a community-based study. Postgrad Med J 1995; 71: 413–8

    Article  PubMed  CAS  Google Scholar 

  6. Megraud F, O’Morain C, Malfertheiner P. Guidelines for clinical trials in Helicobacter pylori infection [abstract]. Gut 1997; 41 Suppl. 2: S17

    Google Scholar 

  7. Desroches JJ, Lahaie RG, Picard M, et al. Methodological validation and clinical usefulness of carbon-14-urea breath test for documentation of presence and eradication of Helicobacter pylori infection. J Nucl Med 1997; 38(7): 1141–5

    PubMed  CAS  Google Scholar 

  8. Slomianski A, Schubert T, Cutler AF. [13C]urea breath test to confirm eradication of Helicobacter pylori. Am J Gastroenterol 1995; 90: 224–6

    PubMed  CAS  Google Scholar 

  9. Labenz J, Peitz U, Aygen S, et al. Accuracy of rapid urease test and urea breath test for diagnosis of Helicobacter pyori infection after treatment: an investigator-blind multicenter study [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A188

    Google Scholar 

  10. van de Wouw BA, de Boer WA, Hermsen HW, et al. Usefulness of the 14C urea breath test as a semi-quantitative monitoring instrument after therapy for Helicobacter pylori infection. Scand J Gastroenterol 1997; 32(2): 112–7

    Article  PubMed  Google Scholar 

  11. Epple HJ, Kirstein FW, Bojarski C, et al. 13C-urea breath test in Helicobacter pylori diagnosis and eradication: correlation to histology, origin of ‘false’ results, and influence of food intake. Scand J Gastroenterol 1997; 32(4): 308–14

    Article  PubMed  CAS  Google Scholar 

  12. Kist M, Strobel S, Fölsch UR, et al. Prospective assessment of the impact of primary antimicrobial resistances on cure rates of Helicobacter pylori infections [abstract]. Gut 1997; 41 Suppl. 1: A90

    Google Scholar 

  13. Shimoyama T, Fukuda Y, Fukuda S, et al. Validity of various diagnostic tests to evaluate cure of Helicobacter pylori infection. J Gastroenterol 1996; 31(2): 171–4

    Article  PubMed  CAS  Google Scholar 

  14. Laine L, Suchower L, Johnson E, et al. Accuracy of CLOtest after Helicobacter pylori therapy. Gastrointest Endosc 1998; 47: 250–3

    Article  PubMed  CAS  Google Scholar 

  15. Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996; 91: 2120–4

    PubMed  CAS  Google Scholar 

  16. Logan RP, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36(1): 12–6

    Article  PubMed  CAS  Google Scholar 

  17. Vigneri S, Termini R, Scialabba A, et al. Omeprazole therapy modifies the gastric localization of Helicobacter pylori. Am J Gastroenterol 1991; 86: 1276

    PubMed  CAS  Google Scholar 

  18. Atherton JC, Cockayne A, Balsitis M, et al. Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine. Gut 1995; 36(5): 670–4

    Article  PubMed  CAS  Google Scholar 

  19. Graham DY, Genta RM. Reinfection with H. pylori. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht: Kluwer Academic Publishers, 1994: 113–20

    Google Scholar 

  20. Xia HX, Talley NJ, Keane CT, et al. Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci 1997; 42(9): 1821–34

    Article  PubMed  CAS  Google Scholar 

  21. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87(12): 1716–27

    PubMed  CAS  Google Scholar 

  22. van der Hulst RWM, Keller JJ, Rauws EAJ, et al. Treatment of Helicobacter pylori infection: areview of the world literature. Helicobacter 1996; 1(1): 6–19

    Article  PubMed  Google Scholar 

  23. Gudjonsson H, Bardhan KD, Hoie O, et al. High H. pylori eradicating rate with a one week triple regimen containing ranitidine bismuth citrate [abstract]. Gut 1997; 41 Suppl. 1: A99

    Google Scholar 

  24. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997; 92: 2213–5

    PubMed  CAS  Google Scholar 

  25. Savarino V, Mansi C, Mele MR, et al. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. Aliment Pharmacol Ther 1997; 11: 699–703

    Article  PubMed  CAS  Google Scholar 

  26. Williams MP, Hamilton MR, Sercombe JC, et al. Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. Aliment Pharmacol Ther 1997; 11: 705–10

    Article  PubMed  CAS  Google Scholar 

  27. Williamson R, Pipkin GA, Wood JR. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. Scand J Gastroenterol 1998; 225 Suppl.: 36–40

    CAS  Google Scholar 

  28. Bertoni G, Sassatelli R, Nigrisoli E, et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996; 91(2): 258–63

    PubMed  CAS  Google Scholar 

  29. Caselli M, Trevisani L, Tursi A, et al. Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1997; 9(1): 45–8

    Article  PubMed  CAS  Google Scholar 

  30. Di Mario F, Dal Bo N, Grassi SA, et al. Azithromycin for the cure of Helicobacter pylori infection. Am J Gastroenterol 1996; 91(2): 264–7

    PubMed  Google Scholar 

  31. Seelis REA, Dohmen W. The synergistic effect of azithromycin and tinidazole in eradicating Helicobacter pylori [abstract]. Gut 1997; 41 Suppl. 1: A102

    Google Scholar 

  32. Tursi A, Cammarota G, Papa A, et al. What is the best azithromycin-based therapy for Helicobacter pylori infection? J Antimicrob Chemother 1997; 39(1): 111

    Article  PubMed  CAS  Google Scholar 

  33. Borody TJ, Andrews P, Fracchia G, et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37(4): 477–81

    Article  PubMed  CAS  Google Scholar 

  34. de Boer WA, Driessen WM, Potters VP, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89(11): 1993–7

    PubMed  Google Scholar 

  35. de Boer WA, Driessen WM, Jansz AR, et al. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. Eur J Gastroenterol Hepatol 1995; 7(12): 1189–94

    Article  PubMed  Google Scholar 

  36. de Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345(8953): 817–20

    Article  PubMed  Google Scholar 

  37. de Boer WA. How to achieve a near 100% cure rate for H. pylori. infection in peptic ulcer patients: a personal viewpoint. J Clin Gastroenterol 1996; 22(4): 313–6

    Article  PubMed  Google Scholar 

  38. Hosking SW, Ling TK, Chung SC, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508–10

    Article  PubMed  CAS  Google Scholar 

  39. van der Hulst RW, van der Ende A, Homan A, et al. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998; 42: 166–9

    Article  PubMed  Google Scholar 

  40. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996; 1(3): 138–44

    Article  PubMed  CAS  Google Scholar 

  41. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997; 41: 735–9

    Article  PubMed  CAS  Google Scholar 

  42. Cardelli A, Cordiano C, Giglio A, et al. A new dual 7-day therapy is effective in eradicating Helicobacter pylori in duodenal ulcer patients [abstract]. Gut 1997; 41 Suppl. 1: A96

    Google Scholar 

  43. Dammann HG, Fölsch UR, Hahn EG, et al. 7 vs 14 days treatment with pantoprazole, clarithromycin and metronidazole for cure of H. pylori infection in duodenal ulcer patients [abstract]. Gut 1997; 41 Suppl. 1: A103

    Google Scholar 

  44. Hermida C, Fernandez-Munoz J, Perez-Poveda JJ, et al. Triple therapy omeprazol (O) + amoxicillin (A) + clarithromycin (C) for Helicobacter pylori (HP) infection: 6 vs 12 days. Results and cost analysis [abstract]. Gut 1997; 41 Suppl. 1: A94

    Google Scholar 

  45. Krause R, Pruitt R, Lukasik N, et al. 10 vs 14 day triple therapy with lansoprazole (PrevacidR), amoxicillin and clarithromycin in the eradication of Helicobacter pylori (Hp) [abstract]. Gut 1997; 41 Suppl. 1: A101

    Google Scholar 

  46. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 1029–33

    Article  PubMed  CAS  Google Scholar 

  47. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection: factors influencing the treatment success. Scand J Gastroenterol 1994; 29(12): 1070–5

    Article  PubMed  CAS  Google Scholar 

  48. de Boer WA, van Etten RJXM. Weekend lansoprazole-quadruple therapy for Helicobacter pylori infection [abstract]. Gut 1997; 41 Suppl. 1: A97

    Google Scholar 

  49. de Boer WA, van Etten RJXM, Schneeberger PM. Four days lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection [abstract]. Gut 1997; 41 Suppl. 1: A101

    Google Scholar 

  50. de Boer WA, van Etten RJ, Schade RW, et al. One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11(1): 109–12

    Article  PubMed  Google Scholar 

  51. de Boer WA, van Etten RJ, Schade RW, et al. 4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am J Gastroenterol 1996; 91(9): 1778–82

    PubMed  Google Scholar 

  52. Peitz U, Nusch A, Tillenburg B, et al. Impact of treatment duration and metronidazole resistance on H. pylori cure rate with omeprazole, metronidazole, and clarithromycin [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A255

    Google Scholar 

  53. Buda A, Dal Bo N, Kusstatscher S. Different lansoprazole dosages in H. pylori eradication therapy: a prospective multicenter randomized study comparing 30 mg b.i.d. vs 15 mg b.i.d [abstract]. Gut 1997; 41 Suppl. 1: A92

    Google Scholar 

  54. Kayser S, Flury R, Zbinden R, et al. Wirkungsvergleich von Lansoprazol/Amoxicillin mit Omeprazol/Amoxicillin zur Eradikation von Helicobacter pylori bei Patienten mit Duodenalulkus. Schweiz Med Wochenschr 1997; 127(17): 722–7

    PubMed  CAS  Google Scholar 

  55. Malfertheiner P, von Arnim U, Stolte M, et al. Lansoprazole short term triple therapy (TT) is highly effective to cure H. pylori infection following dual therapy (DT) failures [abstract]. Gut 1997; 41 Suppl. 3: A52

    Google Scholar 

  56. Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for cure of H. pylori infection [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A 53

    Google Scholar 

  57. Gupta VK, Dhar A, Srinivasan S, et al. Eradication of//, pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 1997; 92: 1140–2

    PubMed  CAS  Google Scholar 

  58. Bazzoli F, Zagari RM, Fossi S, et al. Short term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773–7

    Article  Google Scholar 

  59. Lamouliatte H, The Aquitaine Gastro Association, de Mascarel A. Double-blind study comparing once daily versus twice daily dosage of PPI with amoxicillin-clarithromycin for H. pylori cure [abstract]. Gut 1997; 41 Suppl. 1: A93

    Article  Google Scholar 

  60. Schütze K, Hentschel E, Hirschl AM. Duodenal ulcer healing after 7-day treatment with amoxicillin, metronidazole and omeprazole (20 vs 40mg) without acid suppression [abstract]. Gut 1997; 41 Suppl. 1: A98

    Google Scholar 

  61. O’Connor HJ, Loane J, Bindel H, et al. One week triple therapy fox Helicobacter pylori: does high-dose clarithromycin confer additional benefit. Helicobacter 1997; 2(4): 199–204

    Article  PubMed  Google Scholar 

  62. Labenz J, Beker JA, Dekker CP, et al. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxy-cillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11(3): 515–22

    Article  PubMed  CAS  Google Scholar 

  63. Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997; 11(2): 323–9

    Article  PubMed  CAS  Google Scholar 

  64. Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39–43

    Article  PubMed  CAS  Google Scholar 

  65. Sjöstedt S, Sagar M, Lindberg G, et al. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol 1998; 33: 39–43

    Article  PubMed  Google Scholar 

  66. Kleveland PM, Waldum HL, Brenna E, et al. Relationship between the efficacy of amoxicillin and intragastric pH for the treatment of Helicobacter pylori infection. Helicobacter 1997; 2: 144–8

    Article  PubMed  CAS  Google Scholar 

  67. Lind T, Megraud F, Bardhan K, et al. The MACH 2 Study: antimicrobial resistance in Helicobacter pylori therapy. The impact of omeprazole [abstract]. Gut 1997; 41 Suppl. 1: A89

    Google Scholar 

  68. Laine L, Frantz JE, Baker A, et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 913–7

    Article  PubMed  CAS  Google Scholar 

  69. Veldhuyzen van Zanten S, Hunt RH, Cockeram A, et al. Adding once-daily omeprazole 20mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol 1998; 93: 2–3

    Google Scholar 

  70. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412–7

    Article  PubMed  CAS  Google Scholar 

  71. Annibale B, D’Ambra G, Luzzi I, et al. Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol 1997; 92(5): 790–4

    PubMed  Google Scholar 

  72. Adamek RJ, Pfaffenbach B, Szymanski C. Does pre-treatment with pantoprazole affect the efficacy of a modern triple therapy in HP cure [abstract]? Gastroenterology 1997; 112 (4 Suppl.): A53

    Google Scholar 

  73. Xia HX, Buckley M, Keane CT, et al. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996; 37(3): 473–81

    Article  PubMed  CAS  Google Scholar 

  74. DeCross AJ, Marshall BJ, McCallum RW, et al. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol 1993; 31: 1971–4

    Google Scholar 

  75. Knapp CC, Ludwig MD, Washington JA. In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion. Antimicrob Agents Chemother 1991; 35: 1230–1

    Article  PubMed  CAS  Google Scholar 

  76. Henriksen TH, Brorson O, Schoyen R, et al. A simple method for determining metronidazole resistance of Helicobacter pylori. J Clin Microbiol 1997; 35(6): 1424–6

    PubMed  CAS  Google Scholar 

  77. Glupczynski Y, European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777–81

    Article  Google Scholar 

  78. Megraud F.H. pylori resistance to antibiotics. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht: Kluwer Academic Publishers, 1994: 570–83

    Google Scholar 

  79. Ling TK, Cheng AF, Sung JJ, et al. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1996; 1: 57–61

    Article  PubMed  CAS  Google Scholar 

  80. De Koster E, Cozzoli A, Vandenborre C, et al. HP resistance to macrolides increases, to imidazoles remains stable [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A99

    Google Scholar 

  81. Loo VG, Fallone CA, De Souza E, et al. In vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metro-nidazole and omeprazole. J Antimicrob Chemother 1997; 40: 881–3

    Article  PubMed  CAS  Google Scholar 

  82. Tillenburg B, Siehoff S, Becker T, et al. Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area). Z Gastroenterol 1997; 35: 165–9

    PubMed  CAS  Google Scholar 

  83. Miyaji H, Azuma T, Ito S, et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin, and amoxi-cillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997; 11: 1131–6

    Article  PubMed  CAS  Google Scholar 

  84. Han DS, Cho YJ, Sohn JH, et al. Antimicrobial resistance of Helicobacter pylori in Korean duodenal ulcer patients [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A138

    Google Scholar 

  85. van Zwet AA, de Boer WA, Schneeberger PM, et al. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur J Clin Microbiol Infect Dis 1996; 15(11): 861–4

    Article  PubMed  Google Scholar 

  86. Cabrita J, Oleastro M, Manhente A. Evolution of Helicobacter pylori antibiotic resistance in Portugal (1990–97) [abstract]. Gut 1997; 41 (Suppl. 1): A99

    Google Scholar 

  87. Weissfeld A, Haber M, Rose P, et al. Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with Helicobacter pylori [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A328

    Google Scholar 

  88. Wolle K, Nilius M, Leodolter A, et al. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis 1998; 17: 519–21

    PubMed  CAS  Google Scholar 

  89. Karim QN, Logan RPH. The epidemiology of Helicobacter pylori antimicrobial resistance: preliminary findings of a national survey [abstract]. Gut 1995; 37 Suppl. 2: A6

    Google Scholar 

  90. Banatvala N, Davies GR, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994; 35(11): 1562–6

    Article  PubMed  CAS  Google Scholar 

  91. Katelaris PH, Nguyen TV, Robertson GJ, et al. Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. Aust N Z J Med 1998; 28: 633–8

    Article  PubMed  CAS  Google Scholar 

  92. Megraud F. What is the relevance of resistance of Helicobacter pylori to antimicrobial agents? In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht/Boston/London: Kluwer Academic Publishers, 1996: 348–56

    Google Scholar 

  93. Megraud F, Pichavant R, Palegry D, et al. Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997; 41 Suppl. 1: A92

    Google Scholar 

  94. Lopez Brea M, Domingo D, Sanchez I, et al. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrob Chemother 1997; 40(2): 279–81

    Article  PubMed  CAS  Google Scholar 

  95. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432–5

    Article  PubMed  CAS  Google Scholar 

  96. Dore MP, Sepulveda AR, Mura I, et al. Explanation for variability of omeprazole amoxicillin therapy? Tolerance of H. pylori to amoxicillin [abstract]. Gastroenterology 1997; 112: (4) A105

    Google Scholar 

  97. Dore MP, Piana A, Carta M, et al. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 635–9

    Article  PubMed  CAS  Google Scholar 

  98. Midolo PD, Korman MG, Turnidge JD, et al. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347(9009): 1194–5

    Article  PubMed  CAS  Google Scholar 

  99. Piccolomini R, Di Bonaventura G, Catamo G, et al. Comparative evaluation of the E test, agar dilution, and broth micro-dilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 1997; 35(7): 1842–6

    PubMed  CAS  Google Scholar 

  100. de Boer WA, Tytgat GN. How to treat Helicobacter pylori infection: should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 1996; 8(7): 709–16

    PubMed  Google Scholar 

  101. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997; 2(4): 185–7

    Article  PubMed  CAS  Google Scholar 

  102. Wurzer H, Rodrigo L, Stamler D, et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 1997; 11: 943–52

    Article  PubMed  CAS  Google Scholar 

  103. Burette A, Lamy V, Ramdani B, et al. Lansoprazole (30mg od vs bd) with amoxicillin and clarithromycin to cure Helicobacter pylori infection [abstract]. Gut 1996; 39 Suppl. 2: A33

    Google Scholar 

  104. Buckley MJM, Xia HX, Hyde DM, et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42(10): 2111–5

    Article  PubMed  CAS  Google Scholar 

  105. Harris AW, Pryce DI, Gabe SM, et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10(6): 1005–8

    Article  PubMed  CAS  Google Scholar 

  106. Lerang F, Moum B, Haug JB, et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?. Am J Gastroenterol 1997; 92(2): 248–53

    PubMed  CAS  Google Scholar 

  107. Moayyedi P, Sahay P, Tompkins DS, et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995; 7(9): 835–40

    PubMed  CAS  Google Scholar 

  108. Peitz U, Nusch A, Tillenburg B, et al. High cure rate of H. pylori infection by one-week therapy with omeprazole, metronidazole, and clarithromycin despite a negative impact by metronidazole resistance [abstract]. Gut 1996; 39 Suppl. 2: A5

    Article  Google Scholar 

  109. Yousfi MM, El Zimaity HM, al Assi MT, et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9(2): 209–12

    Article  PubMed  CAS  Google Scholar 

  110. Bell GD, Powell KU, Burridge SM, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 41–6

    Article  PubMed  CAS  Google Scholar 

  111. Thijs JC, van Zwet AA, Thijs WJ, et al. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997; 11(2): 305–9

    Article  PubMed  CAS  Google Scholar 

  112. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102(2): 493–6

    PubMed  CAS  Google Scholar 

  113. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88(4): 505–9

    PubMed  CAS  Google Scholar 

  114. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for H. pylori [abstract]. Gut 1997; 41 Suppl. 1: A103

    Google Scholar 

  115. Johnston BJ, Levi S. What is the relevance of the randomised controlled clinical trial in H. pylori eradication to routine clinical practice?. [abstract]. Gut 1997; 41 Suppl. 1: A91

    Google Scholar 

  116. Vakil N, Fennerty B. Cost-effectiveness of H. pylori eradication regimes: Efficacy vs effectiveness [abstract]. Gut 1997; 41 Suppl. 1: A89

    Google Scholar 

  117. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1997; 32(1): 24–7

    Article  PubMed  CAS  Google Scholar 

  118. Georgopoulos SD, Ladas SD, Karatapanis S. Does follicular gastritis adversely affect H. pylori eradication rate [abstract]? Gut 1997; 41 Suppl. 1: A97

    Google Scholar 

  119. Katicic M, Presecki V, Marusic M, et al. Eradication of H. pylori infection with two triple-therapy regimes of 7, 10 and 14 days duration [abstract]. Gut 1997; 41 Suppl. 1: A100

    Article  Google Scholar 

  120. Gisbert JP, Boixeda D, de Rafael Le. Which factor influence on the success of ‘classic’ triple therapy in Helicobacter pylori eradication [abstract]? Gut 1996; 39 Suppl. 2: A7

    Google Scholar 

  121. Sheu BS, Yang HB, Su IJ, et al. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996; 44(6): 683–8

    Article  PubMed  CAS  Google Scholar 

  122. Yang HB, Sheu BS, Su IJ, et al. Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori. eradication. Dig Dis Sci 1997; 42(9): 1835–40

    Article  PubMed  CAS  Google Scholar 

  123. Moshkowitz M, Konikoff FM, Peled Y, et al. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 36(6): 845–7

    Article  PubMed  CAS  Google Scholar 

  124. Gisbert JP, Boixeda D, Martin de Argila C, et al. Existe una correlacion entre las cifras de la prueba del aliento y la respuesta al tratamiento erradicador de Helicobacter pyloril. Rev Esp Enferm Dig 1996; 88(7): 465–9

    PubMed  CAS  Google Scholar 

  125. Malaty H, el-Zimaity HM, Genta RM, et al. High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 1001–4

    Article  PubMed  CAS  Google Scholar 

  126. Zala G, Schwery S, Giezendanner S, et al. Wirksamkeit der Tripeltherapie zur Eradikation von H. pylori bei Therapieversagern mit Omeprazol/Amoxicillin. Schweiz Med Wochenschr 1996; 126(5): 153–8

    PubMed  CAS  Google Scholar 

  127. De Bartolo MR, Reitmayer R, Olson C, et al. Effect of smoking on H. pylori eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole [abstract]. Gut 1995; 37 Suppl. 1: A85

    Article  Google Scholar 

  128. Bardhan KD, Graham DY, Hunt RH, et al. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997; 2: 27–31

    Article  PubMed  CAS  Google Scholar 

  129. Hoffenberg P, Reyes V, Contreras L, et al. Comparison of 2 treatment schemes to eradicate Helicobacter pylori. Rev Med Chil 1995; 123(2): 185–91

    PubMed  CAS  Google Scholar 

  130. Figueroa G, Acuna R, Troncoso M, et al. Low H. pylori. reinfection rate after triple therapy in Chilean duodenal ulcer patients. Am J Gastroenterol 1996; 91(7): 1395–9

    PubMed  CAS  Google Scholar 

  131. Goh KL, Parasakthi N, Chuah SY, et al. Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori: a randomized, double-blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hepatol 1997; 9: 1091–5

    Article  PubMed  CAS  Google Scholar 

  132. Dehesa M, Larisch J, Di Silvio M, et al. Comparison of three seven days pantoprazole based Helicobacter pylori eradication schemes in a Mexican population with highly metronidazole resistant HP strains [abstract]. Gastroenterology 1998; 113 (4 Suppl.): A99

    Article  Google Scholar 

  133. Coelho LG, Passos MC, Chausson Y, et al. Duodenal ulcer and eradication of Helicobacter pylori in a developing country: an 18-month follow-up study. Scand J Gastroenterol 1992; 27(5): 362–6

    Article  PubMed  CAS  Google Scholar 

  134. Louw JA, Lucke W, Jaskiewicz K, et al. Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence. Gut 1995; 36(4): 544–7

    Article  PubMed  CAS  Google Scholar 

  135. Ahuja V, Dhar A, Bal C, et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther 1998; 12: 551–5

    Article  PubMed  CAS  Google Scholar 

  136. Rollan A. Eradication of Helicobacter pylori in developing countries. Rev Med Chil 1997; 125: 939–49

    PubMed  CAS  Google Scholar 

  137. Konar A, Das AS, De PK, et al. Natural history of severe duodenal ulcer disease. Indian J Gastroenterol 1998; 17: 48–50

    PubMed  CAS  Google Scholar 

  138. Buiatti E, Munoz N, Vivas J, et al. Difficulty in eradicating Helicobacter pylori in a population at high risk for stomach cancer in Venezuela. Cancer Causes Control 1994; 5: 249–54

    Article  PubMed  CAS  Google Scholar 

  139. Zaterka S, Eisig JN, Chinzon D, et al. Five day and ten day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer. Rev Hosp Clin Fac Med Sao Paulo 1996; 51: 162–5

    PubMed  CAS  Google Scholar 

  140. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637–41

    Article  PubMed  CAS  Google Scholar 

  141. Zheng ZT, Wang YB. Treatment of peptic ulcer disease with furazolidone. J Gastroenterol Hepatol 1992; 7: 533–7

    Article  PubMed  CAS  Google Scholar 

  142. van Zwet AA, Thijs JC, Van der Wouden EJ, et al. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Aliment Pharmacol Ther 1997; 11: 533–5

    Article  PubMed  Google Scholar 

  143. Xiao SD, Liu WZ, Xia DH, et al. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacier) pylori: a randomized double-blind placebo-controlled clinical trial. Hepatogastroenterology 1990; 37: 503–6

    PubMed  CAS  Google Scholar 

  144. Ramirezramos A, Gilman RH, Leonbarua R, et al. Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Clin Infect Dis 1997; 25(5): 1027–31

    Article  CAS  Google Scholar 

  145. Segura AM, Gutierrez O, Otero W, et al. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 529–32

    Article  PubMed  CAS  Google Scholar 

  146. Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs: a comparative review. Scand J Gastroenterol 1989; 169 Suppl.: 70–80

    Article  CAS  Google Scholar 

  147. Fujimoto S, Marshall B, Blaser MJ. PCR-based restriction fragment length polymorphism typing of Helicobacter pylori. J Clin Microbiol 1994; 32(2): 331–4

    PubMed  CAS  Google Scholar 

  148. Hurtado A, Owen RJ. Identification of mixed genotypes in Helicobacter pylori from gastric biopsy tissue by analysis of urease gene polymorphisms. FEMS Immunol Med Microbiol 1994; 8(4): 307–13

    Article  PubMed  CAS  Google Scholar 

  149. Li CF, Ha TZ, Chi Ds, et al. Differentiation of Helicobacter pylori strains directly from gastric biopsy specimens by PCR-based restriction fragment length polymorphism analysis with culture. J Clin Microbiol 1997; 35(12): 3021–5

    PubMed  CAS  Google Scholar 

  150. Hua J, Birac C, Xia H, et al. Differentiation of recrudescence and reinfection during relapse of Helicobacter pylori infection [abstract]. Am J Gastroenterol 1994; 89: 1395

    Google Scholar 

  151. Hirschl AM, Richter M, Makristathis A, et al. Single and multiple strain colonization in patients with Helicobacter pylori-associated gastritis: detection by macrorestriction DNA analysis. J Infect Dis 1994; 170(2): 473–5

    Article  PubMed  CAS  Google Scholar 

  152. Majewski SI, Goodwin CS. Restriction endonuclease analysis of the genome of Campylobacter pylori with a rapid extraction method: evidence for considerable genomic variation. J Infect Dis 1988; 157(3): 465–71

    Article  PubMed  CAS  Google Scholar 

  153. Salama SM, Jiang Q, Chang N, et al. Characterization of chromosomal DNA profiles from Helicobacter pylori strains isolated from sequential gastric biopsy specimens. J Clin Microbiol 1995; 33(9): 2496–7

    PubMed  CAS  Google Scholar 

  154. Simor AE, Shames B, Drumm B, et al. Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile. J Clin Microbiol 1990; 28(1): 83–6

    PubMed  CAS  Google Scholar 

  155. Vincent P, Gottrand F, Pernes P, et al. High prevalence of Helicobacter pylori infection in cohabiting children: epidemiology of a cluster, with special emphasis on molecular typing. Gut 1994; 35(3): 313–6

    Article  PubMed  CAS  Google Scholar 

  156. Owen RJ, Bickley J, Costas M, et al. Genomic variation in Helicobacter pylori: application to identification of strains. Scand J Gastroenterol 1991; 181 Suppl.: 43–50

    Article  CAS  Google Scholar 

  157. Tee W, Lambert J, Smallwood R, et al. Ribotyping of Helicobacter pylori from clinical specimens. J Clin Microbiol 1992; 30(6): 1562–7

    PubMed  CAS  Google Scholar 

  158. Jorgensen M, Daskalopoulos G, Warburton V, et al. Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: identification from sequential and multiple biopsy specimens. J Infect Dis 1996; 174: 631–5

    Article  PubMed  CAS  Google Scholar 

  159. Mitchell HM, Hu P, Chi Y, et al. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). Gastroenterology 1998; 114: 256–61

    Article  PubMed  CAS  Google Scholar 

  160. Schütze K, Hentschel E, Dragosics B, et al. Helicobacter pylori reinfection with identical organisms: transmission by the patients’ spouses. Gut 1995; 36(6): 831–3

    Article  PubMed  Google Scholar 

  161. Xia HX, Windle HJ, Marshall DG, et al. Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting. Gut 1995; 37(1): 30–4

    Article  PubMed  CAS  Google Scholar 

  162. Fraser AG, Bickley J, Owen RJ, et al. DNA fingerprints of Helicobacter pylori before and after treatment with omeprazole. J Clin Pathol 1992; 45(12): 1062–5

    Article  PubMed  CAS  Google Scholar 

  163. Owen RJ, Bickley J, Hurtado A, et al. Comparison of PCR-based restriction length polymorphism analysis of urease genes with rRNA gene profiling for monitoring Helicobacter pylori infections in patients on triple therapy. J Clin Microbiol 1994; 32(5): 1203–10

    PubMed  CAS  Google Scholar 

  164. Fraser AG, Moore L, Berry S, et al. Eradication treatment for Helicobacter pylori in general practice. N ZMed J 1996; 109(1033): 422–4

    CAS  Google Scholar 

  165. Taylor NS, Fox JG, Akopyants NS, et al. Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting. J Clin Microbiol 1995; 33(4): 918–23

    PubMed  CAS  Google Scholar 

  166. Langenberg W, Rauws EA, Widjojokusumo A, et al. Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. J Clin Microbiol 1986; 24(3): 414–7

    PubMed  CAS  Google Scholar 

  167. van der Hülst RW, Rauws EA, Koycu B, et al. Helicobacter pylori reinfection is virtually absent after successful eradication. J Infect Dis 1997; 176(1): 196–200

    Article  PubMed  Google Scholar 

  168. Miyaji H, Kohli Y, Azuma T, et al. Endoscopie cross-infection with Helicobacter pylori. Lancet 1995; 345(8947): 464

    PubMed  CAS  Google Scholar 

  169. Abu-Mahfouz MZ, Prasad VM, Santogade P, et al. Helicobacter pylori recurrence after successful eradication: a 5-year follow-up in the United States. Am J Gastroenterol 1997; 92(11): 2025–8

    PubMed  CAS  Google Scholar 

  170. Bell GD, Powell KU. Helicobacter pylori reinfection after apparent eradication: the Ipswich experience. Scand J Gastroenterol 1996; 215 Suppl.: 96–104

    Article  CAS  Google Scholar 

  171. George LL, Borody TJ, Andrews P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990; 153(3): 145–9

    PubMed  CAS  Google Scholar 

  172. Labenz J, Tillenburg B, Peitz U, et al. Long-term consequences of Helicobacter pylori eradication: clinical aspects. Scand J Gastroenterol 1996; 215 Suppl.: 111–5

    Article  CAS  Google Scholar 

  173. Miehlke S, Lehn N, Meining A, et al. Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy. Eur J Gastroenterol Hepatol 1996; 8(12): 1161–3

    Article  PubMed  CAS  Google Scholar 

  174. Parsonnet J, Blaser MJ, Perez-Perez GI, et al. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 1992; 102(1): 41–6

    PubMed  CAS  Google Scholar 

  175. Kuipers EJ, Pena AS, van Kamp G, et al. Seroconversion for Helicobacter pylori. Lancet 1993; 342(8867): 328–31

    Article  PubMed  CAS  Google Scholar 

  176. Cullen DJ, Collins BJ, Christiansen KJ, et al. When is Helicobacter pylori infection acquired? Gut 1993; 34(12): 1681–2

    Article  PubMed  CAS  Google Scholar 

  177. Banatvala N, Kashiwagi S, Abdi Y, et al. H. pylori seroconversion and seroreversion in an Okinawan cohort followed for 10 years [abstract]. Am J Gastroenterol 1994; 89: 1300

    Google Scholar 

  178. Xia HX, Gilvarry J, Beattie S, et al. Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens. Am J Gastroenterol 1995; 90(8): 1221–5

    PubMed  CAS  Google Scholar 

  179. Bardhan PK. Epidemiological features of Helicobacter pylori infection in developing countries. Clin Infect Dis 1997; 25: 973–8

    Article  PubMed  CAS  Google Scholar 

  180. Bouali MR, Khediri MF, Ben Rejeb A, et al. Low reinfection rate of H. pyori infection in duodenal ulcer patients [abstract]. Gastroenterology 1997; 12 (4 Suppl.): A78

    Google Scholar 

  181. Zaterka S, Chinzon D, Eisig JN, et al. Reinfection by H. pylori in a developing country: a five years follow up study [abstract]. Am J Gastroenterol 1995; 90(9): 1596

    Google Scholar 

  182. Kim N, Lim SH, Lee KH, et al. Helicobacter pylori reinfection rate and duodenal ulcer recurrence [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A174

    Google Scholar 

  183. Enroth H, Engstrand L. Immunomagnetic separation and PCR for detection of Helicobacter pylori in water and stool specimens. J Clin Microbiol 1995; 33: 2162–5

    PubMed  CAS  Google Scholar 

  184. Kelly SM, Pitcher MC, Farmery SM, et al. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107: 1671–4

    PubMed  CAS  Google Scholar 

  185. Mapstone NP, Lynch DA, Lewis FA, et al. PCR identification of Helicobacter pylori in faeces from gastritis patients. Lancet 1993; 341: 447

    Article  PubMed  CAS  Google Scholar 

  186. Hulten K, Han SW, Enroth H, et al. Helicobacter pylori in the drinking water in Peru. Gastroenterology 1996; 110: 1031–5

    Article  PubMed  CAS  Google Scholar 

  187. Bamford KB, Bickley J, Collins JS, et al. Helicobacter pylori: comparison of DNA fingerprints provides evidence for intrafamilial infection. Gut 1993; 34: 1348–50

    Article  PubMed  CAS  Google Scholar 

  188. Drumm B, Perez-Perez GI, Blaser MJ, et al. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 1990; 322: 359–63

    Article  PubMed  CAS  Google Scholar 

  189. Wang JT, Sheu JC, Lin JT, et al. Direct DNA amplification and restriction pattern analysis of Helicobacter pylori in patients with duodenal ulcer and their families. J Infect Dis 1993; 168: 1544–8

    Article  PubMed  CAS  Google Scholar 

  190. Perez-Perez GI, Witkin SS, Decker MD, et al. Seroprevalence of helicobacter pylori infection in couples. J Clin Microbiol 1991; 29: 642–4

    PubMed  CAS  Google Scholar 

  191. Prasad V, Abu-Mahfouz M, Santogade P, et al. H. pylori reinfection does not occur in treated patients living with untreated H. pylori positive spouses: 5 year study [abstract]. Gastroenterology 1996; 110 (4 Suppl.): A233

    Google Scholar 

  192. Rowland M, Kumar D, O’Connor P, et al. Reinfection with Helicobacter pylori in children [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A273

    Google Scholar 

  193. Kato S, Abukawa D, Furuyama N, et al. Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterol Nutr 1998; 27: 543–6

    Article  PubMed  CAS  Google Scholar 

  194. Oderda G, Vaira D, Ainley C, et al. Eighteen month follow up of Helicobacter pylori positive children treated with amoxy-cillin and tinidazole. Gut 1992; 33(10): 1328–30

    Article  PubMed  CAS  Google Scholar 

  195. van der Hulst RW, Weel JF, van der Ende A, et al. Therapeutic options after failed Helicobacter pylori eradication therapy. Am J Gastroenterol 1996; 91(11): 2333–7

    PubMed  Google Scholar 

  196. Labenz J, Ruhl GH, Bertrams J, et al. Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease. Aliment Pharmacol Ther 1994; 8(3): 323–7

    Article  PubMed  CAS  Google Scholar 

  197. Atherton JC, Hawkey CJ, Spiller RC. Retreatment of Helicobacter pylori infection with amoxicillin and omeprazole in patients failing this regime is less successful than initial treatment [abstract]. Gastroenterology 1994; 106 (4 Suppl.): A42

    Google Scholar 

  198. Rinaldi V, Zullo A, Pugliano F, et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997; 11: 929–33

    Article  PubMed  CAS  Google Scholar 

  199. Treiber G, Ammon S, Schneider E. AMOC: a sort new quadruple therapy vs standard triple therapy for Helicobacter pylori eradication [abstract]. Gut 1997; 41 (Suppl. 1): A96

    Google Scholar 

  200. Moshkowitz M, Konikoff FM, Peled Y, et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Aliment Pharmacol Ther 1996; 10(6): 1015–9

    Article  PubMed  CAS  Google Scholar 

  201. Borody TJ, Shortis NP, Chongnan J, et al. Eradication failure after H. pylori treatment: further therapies [abstract]. Gastroenterology 1996; 110 (4 Suppl.): A67

    Google Scholar 

  202. Peitz U, Nusch A, Sulliga M, et al. Second line treatment of Helicobacter pylori (HP) infection [abstract]. Gut 1997; 41 Suppl. 1: A104

    Google Scholar 

  203. Seppälä K, Sipponen P, Nuutinen H, et al. Intent to treat metro-nidazole resistant H. pylori infection to 100% of cure: therapy with quadruple therapy and its modification [abstract]. Gastroenterology 1995; 108 (4 Suppl.): A216

    Google Scholar 

  204. van Zwet AA, Thijs JC, Oom JAJ, et al. Failure to eradicate H. pylori. in patients with metronidazole resistant strains. Eur J Gastroenterol Hepatol 1993; 5: 185–6

    Article  Google Scholar 

  205. Noach LA, Langenberg WL, Bertola MA, et al. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26: 321–7

    Article  PubMed  CAS  Google Scholar 

  206. Borody TJ, Andrews P, Shortis NP. Features of patients who fail all attempts at Helicobacter pylori eradication [abstract]. Am J Gastroenterol 1994; 89 Suppl.: 1365

    Google Scholar 

  207. Goddard AF, Logan R, Atherton JCE. Maastricht consensus report regimen for second-line treatment of H. pylori infection: how does it perform in practice [abstract]? Gut 1997; 41 Suppl. 1: A96

    Google Scholar 

  208. Lee JM, Fallon C, Breslin NP, et al. H. pylori eradication ‘quadruple therapy’ is effective in ‘triple therapy’ failures [abstract]. Gastroenterology 1997; 112 (4 Suppl.): A195

    Article  Google Scholar 

  209. Goodwin CS, Marshall BJ, Blincow ED, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207–10

    Article  PubMed  CAS  Google Scholar 

  210. Parasakthi N, Goh KL. Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. Am J Gastroenterol 1995; 90(3): 519

    PubMed  CAS  Google Scholar 

  211. Laine L, Suchower L, Frantz J, et al. Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. Aliment Pharmacol Ther 1998; 12: 887–92

    Article  PubMed  CAS  Google Scholar 

  212. Hulten K, Jaup B, Stenquist B, et al. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. Helicobacter 1997; 2: 188–93

    Article  PubMed  CAS  Google Scholar 

  213. Lamarque D, Tankovic J, Berrhouma A, et al. Triple therapy using ciprofloxacin for eradication of clarithromycin and metronidazole-resisiant Helicobacter pylori [abstract]. Gut 1997; 41 Suppl. 1: A104

    Google Scholar 

  214. Dresner D, Coyle W, Nemec R, et al. Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. South Med J 1996; 89: 775–8

    Article  PubMed  CAS  Google Scholar 

  215. Labenz J, Gyenes E, Peitz U, et al. Ciprofloxacin-omeprazole combination therapy for eradication of Helicobacter pylori. Z Gastroenterol 1991; 29(4): 143–5

    PubMed  CAS  Google Scholar 

  216. Logan RP, Gummett PA, Misiewicz JJ, et al. Two-week eradication regimen for metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther 1993; 7: 149–53

    Article  PubMed  CAS  Google Scholar 

  217. Cudia B, Romano M, Gioe FP, et al. “Rescue” therapy including ranitidine bismuth citrate and minocicline and amoxicillin for eradication of Helicobacter pylori in previous H.p. treatment failure [abstract]. Gut 1997; 41 Suppl. 1: A103

    Google Scholar 

  218. Graham DY, Lew GM, Ramirez FC, et al. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection — tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther 1993; 7(1): 111–3

    Article  PubMed  CAS  Google Scholar 

  219. Perri F, Festa V, Andriulli A. Treatment of antibiotic-resistant Helicobacter pylori. N Engl J Med 1998; 339(1): 53

    Article  PubMed  CAS  Google Scholar 

  220. Gisbert JP, Boixeda D, Moreno L, et al. Which therapy should we use when a previous Helicobacter pylori eradication therapy fails [abstract]? Gut 1997; 41 Suppl. 1: A93

    Article  Google Scholar 

  221. Battaglia G, Di Mario F, Vigneri S, et al. Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series. Ital J Gastroenterol Hepatol 1998; 30: 370–4

    PubMed  CAS  Google Scholar 

  222. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404–30

    Article  PubMed  CAS  Google Scholar 

  223. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48(1): 91–132

    Article  PubMed  CAS  Google Scholar 

  224. Coelho LGV, Vieira Wl, Passos MCF, et al. Quadruple therapy for eradication failure or H. pylori reinfection in ulcer patients [abstract]. Gut 1997; 41 Suppl. 1: A94

    Google Scholar 

  225. Crabtree JE. Eradication of chronic Helicobacter pylori infection by therapeutic vaccination. Gut 1998; 43: 7–8

    Article  PubMed  CAS  Google Scholar 

  226. Michetti P. Vaccine against Helicobacter pylori: fact or fiction? Gut 1997; 41: 728–30

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Infectiology, University Hospital, Magdeburg, Leipziger Strasse 44, D-39120, Magdeburg, Germany

    Ulrich Peitz, Andreas Hackelsberger & Peter Malfertheiner

Authors
  1. Ulrich Peitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Hackelsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Malfertheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Peitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peitz, U., Hackelsberger, A. & Malfertheiner, P. A Practical Approach to Patients with Refractory Helicobacter pylori Infection, or Who Are Re-Infected After Standard Therapy. Drugs 57, 905–920 (1999). https://doi.org/10.2165/00003495-199957060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957060-00006

Keywords

Search

Navigation